Ur Metser, MD, FRCPC

Core Lead, Techna Institute for the Advancement of Technology for Health (Techna)
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Keywords: molecular imaging, magnetic resonance imaging (MRI), medical imaging, radiation therapy
  • Clinical applications of functional imaging in oncology
  • Fusion imaging: positron emission tomography, computed tomography, magnetic resonance imaging
  • Novel radiopharmaceuticals targeting tumors
  • Metabolic response assessment to therapy
Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.
Radiology. 2018 Dec 04;:181519
Metser U, Prica A, Hodgson DC, Mozuraitis M, Eberg M, Mak V, Green B, Singnurkar A, Dudebout J, MacCrostie P, Tau N, Mittmann N, Langer DL
A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance...
J Nucl Med. 2018 Nov 15;:
Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond GR, Chua SS, Ho B, Johnston E, Pouliot F, Scott A
Quantitative assessment of dynamic 18F-Fluoromethycholine PET and Dynamic Contrast Enhanced MRI in High Risk Prostate Cancer.
Br J Radiol. 2018 Nov 01;:20180568
Tau N, Berlin A, Yeung I, Halankar J, Murphy G, Jhaveri KS, Ghai S, Metser U
Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
AJR Am J Roentgenol. 2018 Oct 17;:W1-W5
Metser U, Chan R, Veit-Haibach P, Ghai S, Tau N
68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Clin Nucl Med. 2018 Sep 21;:
Singh S, Poon R, Wong R, Metser U
Publisher Correction to: 18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival.
Ann Nucl Med. 2018 Jun 20;:
Parvez A, Tau N, Hussey D, Maganti M, Metser U
718F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival.
Ann Nucl Med. 2018 May 12;:
Parvez A, Tau N, Hussey D, Maganti M, Metser U
Measurement of Tumor Hypoxia in Patients With Locally Advanced Cervical Cancer Using Positron Emission Tomography with 18F-Fluoroazomyin Arabinoside.
Int J Radiat Oncol Biol Phys. 2018 Mar 02;:
Han K, Shek T, Vines D, Driscoll B, Fyles A, Jaffray D, Keller H, Metser U, Pintilie M, Xie J, Yeung I, Milosevic M
18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
Br J Radiol. 2018 Mar 02;:20170814
H St A E, U M, M P, J C, P B, P VH, D H, N T
Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.
J Surg Oncol. 2018 Feb;117(2):213-219
Loveday BPT, Knox JJ, Dawson LA, Metser U, Brade A, Horgan AM, Gallinger S, Greig PD, Moulton CA

Pages


 
Core Lead, Techna Institute for the Advancement of Technology for Health (Techna)
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Associate Professor, Department of Medical Imaging, University of Toronto​